While lymphocyte infiltration is a prerequisite for this approach, it appears that non-T-cell inflamed tumours, which are resistant to PD-1/PD-L1 inhibitors and which were more frequent among NY-ESO-1 and PRAME-positive STS in the present study, can still be treated with adoptive T-cell based immunotherapy [38]. This evidence concerns the gene CD274 and neoplasm.